Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

One stock that might be an intriguing choice for investors right now is Akebia Therapeutics, Inc. AKBA. This is because this security in the Medical - Drugs space is seeing solid earnings estimate ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Xoanacyl as a treatment for high phosphate levels ...

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright & Co. on April 4, 2025. The analyst firm set a price target for $7.50 expecting AKBA to rise to within ...

SEC Filings provided by EDGAR Online, Inc.

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

$45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Provided legislative advocacy ...

WBFF- Baltimore, MD — Spring is here and it's time to find your gardening gloves. This morning on FOX45 Morning News, Alex Parker dug into everything Ladew Topiary Gardens has the offer.

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...